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Polycomb dysregulation in gliomagenesis targets
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Malignant gliomas constitute one of the most signiﬁcant areas of unmet medical need, owing
to the invariable failure of surgical eradication and their marked molecular heterogeneity.
Accumulating evidence has revealed a critical contribution by the Polycomb axis of epigenetic
repression. However, a coherent understanding of the regulatory networks affected by
Polycomb during gliomagenesis is still lacking. Here we integrate transcriptomic and
epigenomic analyses to deﬁne Polycomb-dependent networks that promote gliomagenesis,
validating them both in two independent mouse models and in a large cohort of human
samples. We ﬁnd that Polycomb dysregulation in gliomagenesis affects transcriptional
networks associated with invasiveness and de-differentiation. The dissection of these net-
works uncovers Zfp423 as a critical Polycomb-dependent transcription factor whose silencing
negatively impacts survival. The anti-gliomagenic activity of Zfp423 requires interaction with
the SMAD proteins within the BMP signalling pathway, pointing to a novel synergic circuit
through which Polycomb inhibits BMP signalling.
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T
he Polycomb group (PcG) epigenetic axis highlights the
intimate regulatory nexus between development and
cancer, as its members play a critical role in the acquisition,
maintenance and reversion of developmental fate1, whose
alterations can in turn underlie the expansion or restoration
of a dedifferentiated stem-like state that is thought to fuel
the growth of many cancers2. Trimethylation of lysine 27 of
histone H3 (H3K27me3), catalysed by EZH2 or EZH1 within
Polycomb repressive complex 2 (PRC2), is both a major
mechanism for the reversible maintenance of gene silencing3
and one of the few histone posttranslational modiﬁcations for
which bona ﬁde evidence supports a mechanism of propagation
through cell division, thus providing the molecular basis for the
maintenance of aberrant repressive chromatin during cancer
growth4. In particular, convergent lines of evidence implicate
Polycomb developmental functions as critical nodes of
dysregulation during tumorigenesis. First, the majority of genes
that are hypermethylated in cancers on CpG promoters are
pre-marked by H3K27me3 during development, corroborating
the model in which PcG-dependent programmes that orchestrate
normal development can be hijacked in cancer as templates for
aberrant DNA methylation5–7. Second, inappropriate expression
of PcG proteins was directly shown to fuel dedifferentiation8,
and more recently the dynamic acquisition of the bivalent
chromatin conﬁguration featuring both H3K27me3 and
H3K4me3, which has been associated to both embryonic
and tissue-speciﬁc stem cells9, was found to mediate the plastic
interconversion, within the same tumour, of non-cancer stem
cells into cancer stem cells10.
Furthermore, and beyond the developmental aspects of its
function, the PcG system has been also implicated in
other cardinal features of tumorigenesis, including silencing of
the INK4A-ARF-INK4B locus11, promotion of angiogenesis12
and direct control of DNA replication13.
However, we still lack a coherent understanding of the
genome-wide circuits affected by Polycomb during tumorigenesis,
a deﬁcit that has grown more relevant with accumulating
evidence that PcG members can play opposing roles in
tumorigenesis. Besides the ‘classical’ oncogenic properties of
EZH2 (refs 14–16), recent evidence has pointed also to a tumour
suppressor role manifested through either inactivating mutations
of PRC2 members17,18 or histone mutations that were shown to
inhibit PRC2 activity19,20. Indeed, in the case of glioblastoma
(GBM), although EZH2 is very frequently overexpressed, only its
short-term inhibition ameliorates survival, while a longer
depletion exacerbates tumour-related dedifferentiation21. Yet,
although these results underscore the extreme context
dependence of Polycomb involvement in tumorigenesis22, its
molecular basis remains elusive. Even in settings in which EZH2
inhibition proved remarkably effective, as in lymphomas with
gain-of-function mutations, it was not possible to deﬁne
consistent transcriptional outputs, indicating that Polycomb can
regulate different pathways even within the same apparently
homogeneous tumour type15. This diversity of molecular impact
is being linked to what is increasingly recognized, starting from
Polycomb, as the core function of many chromatin modiﬁers,
namely the deﬁnition of cell context-dependent ranges or
thresholds of gene expression rather than the univocal
determination of transcriptional output2,23. In turn, this
grounds the rationale to pursue the elucidation of Polycomb-
dependent programmes in highly deﬁned and physio-
pathologically meaningful tumour models.
Here we address this challenge focusing on malignant gliomas,
which constitute one of the most signiﬁcant unmet medical needs
and present two particularly relevant features: (i) pronounced
heterogeneity among and within tumour types and (ii)
convergent evidence of context-dependent Polycomb
involvement, which is largely limited to its impact on single
genes and has not mechanistically uncovered the diversity
of its target pathways in relation to speciﬁc glioma subtypes
and developmental contexts24–31. Speciﬁcally, we integrate
transcriptomic and epigenomic analyses to deﬁne functionally
relevant PRC2-dependent networks that promote gliomagenesis,
validating them both in mouse models and human samples.
We ﬁnd that PRC2 affects speciﬁc developmental pathways
associated to deﬁning features of the disease. Moreover, the
dissection of PRC2-dependent circuits at distinct stages of
gliomagenic transformation uncovers Zfp423 as a critical
downstream target of PRC2, whose downregulation negatively
impacts survival and whose overexpression impairs gliomagenesis
in a SMAD (small mother against decapentaplegic)-dependent
manner.
Results
Polycomb targets developmental pathways during gliomagenesis.
To deﬁne the gene circuits that are deregulated during
gliomagenesis in a PRC2-dependent manner, we used a
well-established mouse model of gliomagenesis that relies on
the loss of Ink4a/Arf combined with the overexpression of the
constitutively active mutant form of the human epidermal growth
factor receptor (EGFR) known as EGFR variant III (hereafter
indicated as EGFR*), the two most common lesions in human
high-grade gliomas (HGGs)32 (Fig. 1a and Supplementary
Fig. 1a). The model relies on orthotopic transplantation of
early postnatal astrocytes harbouring both lesions (hereafter
Ink4a/Arf / ; EGFR*) and its unique advantage, as depicted in
Fig. 1a, is the deﬁnition of largely homogeneous cell populations
endowed with different tumorigenic potential (non-tumorigenic
primary Ink4a/Arf / astrocytes, hereafter Astro; tumorigenic
Ink4a/Arf / astrocytes expressing EGFR*, hereafter
AstroEGFR*; glioma propagating cells (GPCs) derived
from primary tumours, hereafter PT; and GPCs derived from
secondary tumours, hereafter ST), which constitute a privileged
entry point to dissect the transcriptional and epigenomic
alterations that accrue during gliomagenesis. Importantly, the
Ink4a/Arf-null background allows to study the developmental
features of PRC2-dependent oncogenesis independent of its
control of the INK4A-ARF-INK4B locus11. We ﬁrst validated the
model through a thorough histopathological assessment,
which extended previous observations30, conﬁrming that in
mouse the Ink4a/Arf / ; EGFR* combination recapitulates a
broad range of HGG, ranging from anaplastic astrocytomas,
oligodendrogliomas and oligoastrocytomas to GBM and
gliosarcoma (Supplementary Fig. 1b,c). Next, we focused on
the key transition between AstroEGFR* and PT, and
performed chromatin immunoprecipitation sequencing
(ChIPseq) and RNA sequencing (RNAseq) for H3K27me3, to
investigate the hypothesized redistribution of the PRC2 mark and
its transcriptional impact during gliomagenesis. For this, we
developed an ad hoc computational pipeline that integrates
RNAseq and ChIPseq proﬁles with transcription factor (TF)
motif enrichment analysis (Fig. 1b), to generate mechanistically
testable hypotheses on the relevant Polycomb-dependent circuits.
A transcriptomic analysis of three independent Ink4a/ARF / ;
EGFR* astrocyte batches along with their resulting PT led to the
identiﬁcation of a set of 545 differentially expressed genes (DEGs),
of which 272 are downregulated and 273 upregulated in PT versus
AstroEGFR*. A cluster analysis based on DEGs revealed a clear
clustering by cell type (that is, with tumorigenic astrocytes
segregating away from all primary tumours; Fig. 1c). This pointed
to a major and largely convergent shift in gene expression
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underlying the AstroEGFR*-PT transition. As shown in Fig. 1c
(right), an Ingenuity Pathway Analysis (IPA) for canonical
pathways uncovered the strongest enrichments among the
downregulated DEGs, with a convergent involvement of genes
controlling cell morphogenesis and migration, and belonging to the
top scoring axonal guidance signalling, regulation of epithelial-to-
mesenchymal transition (EMT) and integrin signalling pathways,
whose key regulators have a well-established involvement in
gliomas. Along with the related Reelin signalling pathway, axonal
guidance signalling came out among the best-ranking pathways
also within the upregulated DEGs (Fig. 1c), consistent with its
dual role in regulating cell migration by ﬁne-tuning both attractive
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Figure 1 | Transcriptional changes and H3K27me3 repositioning during gliomagenesis. (a) Schematic representation of the experimental procedure
followed in this study. Brieﬂy, astrocytes derived from cortices of Ink4a/Arf / pups were infected with the human EGFR* and stereotaxically
transplanted into recipient mice. GPCs were derived from PTand re-injected into secondary hosts to assess tumour propagation capability. (b) Schematic
representation of the computational pipeline. RNAseq data were used to identify DEGs between Ink4a/Arf / astrocytes overexpressing the human
EGFR* (referred to as AstroEGFR*) and GPC (referred to as PT). ChIPseq data deﬁned H3K27me3 target genes in the same cell populations. Integration of
the results outlined a subset of genes that are signiﬁcantly downregulated upon de novo H3K27me3 acquisition in PT. TF motif enrichment analysis (MEA)
was performed on DEGs and integrated with RNAseq and ChIPseq data. (c) Left: heatmap of the DEGs between AstroEGFR* and PT. Colours represent Z-
scores of the row-wise normalized expression values of log2 of fragments per kilobase of transcript per million mapped reads (FPKM; red: increased
expression, blue: reduced expression). Right: enrichment analysis for canonical pathways in the DEGs. The probability (P-value) of random association
between the gene set and given terms is calculated using the right-tailed Fisher’s exact test. Only the top ten most signiﬁcant pathways are reported; bar
represents the  log (P-value). (d) Left: heatmap of normalized tag densities, representing the de novo methylated genes in PT. Each row represents a 6-kb
window centred on the gene TSS and extending 3 kb upstream and 3 kb downstream. The signal has been generated by merging the bam ﬁles of the
biological replicates. Right: enrichment analysis for canonical pathways in the same gene set.
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and repulsive cues. Thus, molecules that are generally associated
to repulsive clues, such as Slit2–3 and Shh, appeared to be
downregulated, whereas attractors such as Wnt7b and Vegfa were
upregulated, consistently with the acquisition of the inﬁltrating
capacity that characterizes malignant gliomas. Finally, the
second top-scoring enriched pathway in downregulated DEGs
was human embryonic stem cell (Fig. 1c), whose enrichment was
due to the exclusive involvement of differentiation-promoting
genes. This points to dedifferentiation as a particularly signiﬁcant
feature of gliomagenesis and further extends the insight that gliomas
originate through the reversion of either astrocytes (as in our
experimental system32) or neurons33 to an undifferentiated state.
Consistently, we found that Tgfb3, known to promote neuronal
differentiation34, Bmp4, involved in astrocyte differentiation35, and
Smad7, important in neural fate acquisition36, were all
downregulated in our PT samples.
When we analysed the same cell populations for H3K27me3
distribution, comparing the number of PRC2 targets in each class
of samples revealed a major overall increase of PRC2 marking in
PT, with 2,306 gene hits compared with 668 in AstroEGFR*.
We then compared these gene sets with two previous data sets
that captured distinct aspects of PRC2 developmental control:
(i) the H3K27me3 signature that characterizes cortical neural
progenitors (NPs)37, ﬁnding that although PT samples shared a
statistically signiﬁcant overlap of H3K27me3 target genes with
NPs (92 genes), AstroEGFR* did not show any speciﬁc overlap
(Supplementary Fig. 1e, left); and (ii) the core set of PRC2 targets
whose silencing we found to be required for cell fate reversion to
pluripotency1, ﬁnding that PT samples shared a striking overlap
of H3K27me3 target genes with this core set (732 genes), whereas
AstroEGFR* showed only a minimal overlap (12 genes)
(Supplementary Fig. 1e, right). Together, these results highlight
the extent of developmental dysregulation and dedifferentiation
that characterize this tumour model. Next, to analyse the
dynamics of PRC2 targets, we focused on the 456 genes that
acquire the mark during the transition from AstroEGFR* to PT
consistently across all PT samples (Fig. 1d, left). Also in this case,
axonal guidance signalling and human embryonic stem cell
pathways scored among the top ten in the IPA analysis of
canonical pathway associated to this subset of genes (Fig. 1d,
right). Importantly, de novo targets featured three clearly distinct
enrichment patterns for H3K27me3: (i) that centred on the
transcription start site (TSS), with the typical pattern of great
enrichment right upstream and downstream of the sharp dip
coinciding with the TSS38; (ii) that with a prevalent enrichment
upstream of the TSS ( 3 kb); or (iii) that with a prevalent
enrichment downstream of the TSS (þ 3 kb). Comparison of
expression values for genes belonging to each of the three classes
showed a signiﬁcant downregulation for those in which the
accumulation of the mark included both the TSS and its
downstream region (Supplementary Fig. 1f).
Finally, we integrated the RNAseq and ChIPseq data sets to
pinpoint the genes that, in the AstroEGFR*–PT transition, became
both downregulated and de novo targets of H3K27me3 (Fig. 2a,
left). Remarkably, axonal guidance signalling was strongly
associated with this subset of genes as well, indicating that this
pathway is under direct Polycomb control during the gliomagenic
transition (Fig. 2a, right). Figure 2b,c shows the independent
validation of these ﬁndings for representative members of the
axonal guidance signalling pathway, namely Slit2, Slit3 and Bmp4,
which were tested for H3K27me3 enrichment (Fig. 2b) and
expression (Fig. 2c). Slit2 and Slit3 are two key molecules originally
involved in axon guidance (in which they provide repulsive cues by
binding to their Roundabout receptors)39,40, whose functional
association with glioma emerged with the observation that Slit2 is
epigenetically silenced in gliomas through DNA methylation41,
and that rescue of its expression reduces cell migration both
in vitro and in vivo42. Bmp4 is known to reduce proliferation and
promote astrogenesis35; hence, its silencing further highlights
dedifferentiation as a core feature of gliomagenesis. Interestingly,
the core subset of genes that are both downregulated and acquire
de novo H3K27me3 in the AstroEGFR* to PT transition showed a
highly signiﬁcant overlap with the subset of Polycomb targets that
are signiﬁcantly downregulated during cell reprogramming
(Supplementary Fig. 2a). Among these genes, we found Bmp4
along with other genes involved in cellular differentiation, further
emphasizing the key role played by Polycomb during the
transcriptional shift from astrocytes to primary tumours
(Supplementary Fig. 2b).
Zfp423 is a master Polycomb target during gliomagenesis.
PRC2 had thus far been implicated in gliomagenesis on the basis
of either clinical correlations29 or of its effect on exemplary genes
involved in astroglial differentiation28. By deﬁning a consistent
genome-wide pattern of PRC2 redistribution across independent
glioma samples and characterizing its transcriptional output, our
results enabled a ﬁrst dissection of the speciﬁc contribution of this
epigenetic axis, uncovering two prominent domains of
developmental dysregulation (that is, the control of migration
and differentiation outlined above). However, beyond
these speciﬁc pathways and consistent with recent evidence2,
this approach also conﬁrmed that only a minor portion of the
extensive transcriptional changes that accrue during gliomagnesis
could be directly imputable to aberrant PRC2 occupancy. Thus, to
gain further mechanistic insight into the functional relevance
of H3K27me3 redistribution, we focused on the identiﬁcation of
putative PRC2-dependent master regulator TFs that could mainly
and indirectly account for the transcriptional changes we
observed. For this, we ﬁrst performed a TF motif enrichment
analysis of the DEGs between AstroEGFR* and PT. This analysis
pinpointed 22 candidate master regulator TFs, deﬁned as TFs
whose binding sites were signiﬁcantly enriched among the DEGs
characterizing the AstroEGFR* to PT transition. These genes
were then ranked according to the signiﬁcance of their expression
change and correlated to their H3K27me3 status. As shown in
Fig. 3a, among the 22 predicted candidate master regulator
TFs, Zfp423 was the only one whose repression correlated
with the de novo acquisition of H3K27me3 in PT. Furthermore,
meta-analysis of an RNAseq data set obtained from a
different murine glioma model21 revealed an inverse expression
correlation between the PRC2 enzymatic subunit Ezh2 and
Zfp423, with Ezh2 knockdown resulting in increased Zfp423
expression (Supplementary Fig. 3a). We next conﬁrmed both the
downregulation (Fig. 3b) and the de novo H3K27me3 acquisition
of Zfp423 (Fig. 3c) in a larger cohort of samples, highlighting the
consistency of this silencing circuit.
As recounted above, gliomas display remarkable heterogeneity
both at the histopathological and molecular level. In addition, we
thus analysed a different mouse model that is based on the
overexpression of platelet-derived growth factor beta (PDGF-B) in
cortical NP (see ref. 43 and Fig. 3d), to determine whether the
glioma-associated repression of Zfp423 was consistent across
different tumour-driving mutations. In this case as well, we
characterized homogeneous populations of cells that captured
different disease stages, namely primary, non-tumorigenic NP
sourced from E13.5 telencephali (hereafter NP), tumorigenic NP
overexpressing PDGF-B (hereafter NP PDGFB) and GPCs derived
from primary tumours (hereafter PT) that were able to regrow
tumours upon orthotopic transplantation. Consistent with our
observations from the Ink4a/Arf / ; EGFR* model, we conﬁrmed
a progressive downregulation of Zfp423 along with the increase in
tumorigenic potential (Fig. 3d).
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Zfp423 is downregulated in human gliomagenesis. Although
Zfp423 had not yet been associated to gliomas, a previous study44
found the human orthologue of Zfp423, ZNF423, to be
downregulated in human neuroblastoma. We thus assessed the
expression of ZNF423 in well-deﬁned human GBM samples that
had been previously subdivided according to EGFR expression45
and found it consistently downregulated, regardless of EGFR
levels, with respect to normal human astrocytes (Fig. 4a), thus
conﬁrming the observation from both mouse models. We then
probed a large set of clinical data available from TCGA database
(http://cancergenome.nih.gov/), to investigate the correlation
between ZNF423 expression and patient survival. To this end,
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we interrogated separately low-grade gliomas and GBMs, and
stratiﬁed samples according to the expression of ZNF423. This
analysis revealed a signiﬁcant direct correlation between ZNF423
expression and survival in low-grade gliomas (Fig. 4b), with high
expression associated to longer survival. The correlation held also
in GBM samples, although in this more malignant subset the
trend fell short of the statistical signiﬁcance threshold
(Supplementary Fig. 4a).
In the case of neuroblastoma, ZNF423 displayed a clear trend
of progressively decreased expression with more advanced
tumour stages and lower expression was associated with worst
prognosis. Thus, to generalize our ﬁndings and test whether
ZNF423 behaved similarly in gliomas, we performed a
meta-analysis of a large cohort of expression data from 343
samples of human gliomas deposited at the NCI REpository for
Molecular BRAin Neoplasia DaTa46. As shown in Fig. 4c, we
observed that also in gliomas, ZNF423 downregulation correlated
with higher grade (right panel). Comparable results were obtained
by performing a second meta-analysis on a further independent
cohort of expression proﬁles, comprising 157 expression data
from Gene Expression Omnibus (GEO ID: GSE4290;
Supplementary Fig. 4b). Moreover, when we classiﬁed patients
from the REpository for Molecular BRAin Neoplasia DaTa
database into three groups according to ZNF423 expression on
the basis of their fold change with respect to median expression, a
Kaplan–Meyer analysis for progression-free survival conﬁrmed
that higher levels of ZNF423 correlate with a far better prognosis
compared with mid or low levels (Fig. 4c, left panel), with high
statistical signiﬁcance between high- (f.c.42) and low-expressing
(f.c.o2) tumours (Mantel–Haenszel test, P¼ 1.65218e 5).
Finally, to ground the mechanistic dissection of the role of
Zfp423 dosage in gliomagenesis, we resorted back to our initial
Ink4a/Arf / ; EGFR* murine model and interrogated three
independent batches of tumorigenic astrocytes (AstroEGFR*1,
AstroEGFR*2 and AstroEGFR*3) with comparable Zfp423
expression. When challenged in in-vivo experiments upon
orthotopic transplantation, we found that AstroEGFR*1 and
AstroEGFR*3 yielded gliomas with a shorter survival compared
with AstroEGFR*2 (Fig. 4d). Strikingly, although primary
tumours originated from every astrocyte batch invariably
displayed Zfp423 downregulation, they did so to different
extents, with AstroEGFR*1 and AstroEGFR*3 showing a
greater reduction than AstroEGFR*2 (Fig. 4d), thus conﬁrming
results from human data and validating this model as a sensitive
system to test the physiopathologically relevant role of
Zfp423.
Context-speciﬁc antigliomagenic effect of Zfp423. As higher
levels of Zfp423 were associated to better prognosis in both
humans and mice, we set out to validate its role by forcing its
overexpression in tumorigenic Ink4a/Arf / ; EGFR* astrocytes
and thereby test whether preventing its PRC2-mediated
downregulation would impair or delay gliomagenesis. The three
representative independent batches of tumorigenic astrocytes,
AstroEGFR*1, AstroEGFR*2 and AstroEGFR*3, were thus
infected with a retroviral vector encoding Zfp423 (ref. 47;
hereafter AstroEGFR* Zfp423). Following conﬁrmation of
overexpression (Fig. 5a), cells were then assessed for
tumorigenicity by sterotactic inoculation. Interestingly, the three
AstroEGFR* lines responded differently to the challenge of
Zfp423 overexpression (Fig. 5b). As shown in Fig. 5b, the
overexpression of Zfp423 had a major impact on the
tumorigenicity of AstroEGFR*2 astrocytes, with a highly
statistically signiﬁcant increase in survival (P¼ 0.0089). On the
contrary, mice transplanted with either AstroEGFR*1 or
AstroEGFR*3 astrocytes showed different survivals. Speciﬁcally,
although AstroEGFR*1, which reached overexpression levels
comparable to those in AstroEGFR*2, showed a trend of extended
survival that did not reach statistical signiﬁcance, AstroEGFR*3,
despite much stronger Zfp423 overexpression, displayed a shorter
survival. To gain insight into the molecular underpinnings of the
differential response to Zfp423 overexpression, we followed two
complementary approaches.
First, we performed a principal component analysis of the
AstroEGFR* transcriptomes, which revealed that AstroEGFR*
cluster according to their responsiveness to Zfp423 overexpression
(Fig. 6a). Differential expression analysis uncovered gene clusters
that were distinctly associated to each batch (Fig. 6b), which we
then used to query PT transcriptomes ﬁnding that PT originated
from AstroEGFR*1 and AstroEGFR*3, when compared with the
AstroEGFR*2-derived PT, retained expression of a larger portion
of the gene cluster belonging to the respective astrocyte batch
(Fig. 6c). On the contrary, a shufﬂing analysis that randomly
queried astrocyte batch-speciﬁc clusters against PT did not reveal
the same degree of retention (Supplementary Fig. 5a). This
establishes that a signiﬁcant fraction of the gene expression that
distinguishes similar yet distinct batches of tumorigenic astrocytes
is retained in the respective tumours. Furthermore, it highlights
how such tumour-retained gene expression is already primed to a
greater extent in the Zfp423-resistant astrocyte batches that display,
accordingly, a more aggressive tumorigenicity. This ﬁnding was
strengthened by an unsupervised cluster analysis of the
transcriptomes of the three AstroEGFR* and the respective PT.
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Figure 6 | Zfp423 overexpression differentially affects AstroEGFR* networks. (a) Variable factor map (principal component analysis (PCA))
representing the degree of correlation between AstroEGFR* transcriptomes. The PCA shows that AstroEGFR* cluster according to their responsiveness to
Zfp423 overexpression. Correlation coefﬁcients of AstroEGFR*1, AsrtoEGFR*2 and AstroEGFR*3 with the ﬁrst component are 0.8499869, 0.5120449 and
0.8380024, respectively. (b) Heatmap representing the clusters of genes selectively enriched in the three batches of tumorigenic astrocytes. (c) Pie charts
representing the proportion of tumour-retained gene expression for each AstroEGFR*-derived PT. (d) Venn diagrams showing the overlap of Zfp423-
dependent genes identiﬁed in the three different astrocytes batches upon Zfp423 overexpression. (e) Gene set enrichment analysis showing the
enrichment, within the DEGs initially identiﬁed between AstroEGFR* and PT, for Zfp423-dependent genes. The interrogation with the Zfp423-dependent
genes upregulated in AstroEGFR*2 shows a signiﬁcant enrichment in the DEGs that are downregulated in the gliomagenic transition from tumorigenic
astrocytes to primary gliomas. Black bars represent the position of Zfp423-dpendent genes in the ranked list of DEGs between AstroEGFR* and PT. The
green line represents the enrichment score. The nominal P-values associated with the Zfp423-dependent genes upregulated in AstroEGFR*2, the Zfp423-
dependent genes upregulated in AstroEGFR*3 and the Zfp423-dependent genes downregulated in AstroEGFR*3 are statically signiﬁcant (Po0.01).
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Indeed, each AstroEGFR* clusters with the corresponding tumour
(Supplementary Fig. 5b), indicating that each AsroEGFR* batch is
already seeded with partially speciﬁc transcriptional programmes
that will unfold during tumour development.
Second, we compared by RNAseq the transcriptomes of the
three batches of AstroEGFR* to their respective transcriptomes
upon forced Zfp423 expression (AstroEGFR*1 versus Astro-
EGFR*1 Zfp423, AstroEGFR*2 versus AstroEGFR*2 Zfp423 and
AstroEGFR*3 versus AstroEGFR*3 Zfp423) and went on
to deﬁne the Zfp423-centred transcriptional interactions speciﬁc
to each pair. To this end, we integrated the results of differential
expression obtained from each comparison with a co-expression-
based analysis extracted from a large data set of 106 gene
expression proﬁles collected in the GeneMania database48. The
aim was ﬁrst to infer the high conﬁdence co-expression networks
centred on Zfp423 and then deﬁne which portion of these
predicted circuits were empirically validated in Zfp423-responsive
versus Zfp423-non-responsive tumorigenic astrocytes. Consistent
with the in-vivo outcome, interrogation of these gene networks
showed that Zfp423 overexpression had affected different sets of
genes in the three batches of tumorigenic astrocytes (Fig. 6d).
We thus reasoned that these distinct gene subsets should display
marked differences with respect to the transcriptional programme
that underlies primary gliomagenesis in the same murine model.
To test this hypothesis, we thus compared, by gene set
enrichment analysis, the Zfp423-dependent genes speciﬁcally
affected in each batch of tumorigenic astrocyte with the DEGs
that marked the AstroEGFR*-to-PT transition. This approach
conﬁrmed that the genes downregulated in the AstroEGFR*-to-
PT transition were signiﬁcantly enriched for the Zfp423-
dependent genes that were upregulated speciﬁcally in
AstroEGFR*2, providing a clear molecular basis for the
antigliomagenic effect of Zfp423 in this context. On the
contrary, although we did not ﬁnd any signiﬁcant enrichment
for Zfp423-dependent genes affected in AstroEGFR*1, we found a
signiﬁcant enrichment for the Zfp423-dependent genes affected in
AstroEGFR*3, but among the genes that changed in the same
direction as the DEGs characterizing the AstroEGFR*-to-PT
transition (Fig. 6e), again providing the molecular
correlate for the lack of antigliomagenic effect by Zfp423
in this context. Together, these results provide a molecular
basis for the antigliomagenic impact of Zfp423 in the speciﬁc
cellular context of AstroEGFR*2, grounding it in the ability
to speciﬁcally antagonize a signiﬁcant portion of the
gliomagenesis-speciﬁc transcriptional programme that
characterizes this murine model.
Interestingly, among the genes speciﬁc to the Zfp423 response
there are several members of the axon guidance pathways and
tumour suppressor genes whose modulation was already
associated to reduced tumorigenicity: namely Slit2 (refs 41,42),
Pappa49, Nfatc4 (ref. 50) and Lox51. Furthermore, the group of
genes speciﬁcally downregulated upon Zfp423 overexpression
only in AstroEGFR*2 and not in AstroEGFR*1 or AstroEGFR*3
included also Sox2 and several other Sox family genes
(Supplementary Fig. 5c), which have recently emerged as
important driving or enabling factors in gliomagenesis52,53. As
TF motif analysis predicted that the Sox2 promoter contains a
putative binding site for Zfp423, we asked whether Zfp423
overexpression could antagonize gliomagenesis by repressing
Sox2 in Zfp423-responsive astrocytes. To test this hypothesis, we
overexpressed Sox2 in Zfp423-responsive astrocytes to revert the
phenotype of extended survival, using a construct that lacked
endogenous control regions and thus could not be subjected to
Zfp423 transcriptional repression. Indeed, the overexpression of
Sox2 in the context of Zfp423 overexpression showed a survival
rate that was much shorter compared with that achieved with
Zfp423 overexpression alone (Fig. 7a), thus establishing Sox2
downregulation as a fundamental antigliomagenic event
downstream of Zfp423 overexpression. Interestingly, however,
against the expected accelerated tumorigenesis induced by
overexpression of Sox2 alone, mice receiving astrocytes
overexpressing both TFs showed longer survival (Fig. 7a),
uncovering also a mutually antagonistic indirect circuit between
Zfp423 and Sox2 in gliomagenesis.
Finally, in light of these analyses indicating that the Ink4a/
Arf / ; EGFR* paradigm is more diverse than previously
anticipated, we investigated this diversity considering the
pronounced heterogeneity characterizing human HGG, as
captured in recent molecular classiﬁcations24–26. Speciﬁcally,
we used the signatures deﬁned by Phillips et al.24 to interrogate
our cohort of PT samples and determine the extent to which they
ﬁt this classiﬁcation, while measuring the spread of their
molecular diversity. Notably, most murine models of glioma
have not yet been interrogated with human signatures; thus, this
analysis also provided a ﬁrst characterization of the human
equivalence, at the molecular level, of the Ink4a/Arf / ; EGFR*
model. We found that although no PT ﬁt neatly into either
of the three categories (proneural, proliferative or mesenchymal),
each encompassed different partitions of the three signatures,
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Figure 7 | Zfp423 expression antagonizes gliomagenesis in a SMAD-
dependent manner. (a) Kaplan–Meyer analysis of survival in mice injected
with AstroEGFR*2 overexpressing either Zfp423, Sox2 or both.
Reconstitution of Sox2 expression in the context of Zfp423 overexpression
reverted the Zfp423-dependent antigliomagenic phenotype (orange line),
leading to shorter survival compared with Zfp423 overexpression alone
(purple line). Overexpression of both Zfp423 and Sox2 also prolonged
survival with respect to Sox2 overexpression alone, indicating mutual
antagonism between the two factors. Numbers of animals for each category
are indicated in brackets in the caption; P-values were computed with
log-rank Mantel–Cox test. (b) Overexpression of a mutant form of Zfp423
lacking the SMAD-binding domain (Zfp423DSBD, dark grey curve) fails to
prolong survival in mice. Numbers of animals for each category are
indicated in brackets in the caption; P-values were computed with log-rank
Mantel–Cox test.
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with a prevalence of the mesenchymal one (Supplementary
Fig. 5d). Interestingly, most of these partitions showed
opposite trends in different samples, pointing to a fundamental
level of heterogeneity that accompanies, in a preferentially
mesenchymal background, Ink4a/Arf / ; EGFR*-driven
gliomagenesis.
The Zfp423 antigliomagenic role engages BMP-SMAD signalling.
Zfp423 is widely involved in differentiation47,54–60. Consistently,
we had previously found it greatly downregulated upon
reprogramming of mouse embryonic ﬁbroblasts into induced
pluripotent stem cells1. Of special relevance, Zfp423 belongs also
to the genes speciﬁcally expressed in the astrocyte lineage61, a
ﬁnding that we further corroborated by inducing astrocytic
differentiation and conﬁrming the expected BMP4-enhanced
upregulation of Zfp423 (Supplementary Fig. 6a).
ZFP423 exerts its differentiation-promoting function by binding,
through zinc ﬁngers 14–20, to SMAD proteins62,63 that mediate
response to bone morphogenetic protein (BMP) signalling in
different cell types62 (Supplementary Fig. 6b). In our PT samples,
both Bmp4 and Zfp423 are de novo H3K27 trimethylated and
downregulated, pointing to a double and synergic blockade of the
BMP signalling pathway that is critical for astroglial differentiation.
Thus, also in light of the observation that Zfp423 can coordinate
BMP and Notch signalling throughout neural development, and
that this effect is enhanced after BMP4 stimulation63, we infected
the Zfp423-sensitive astrocytes (that is, AstroEGFR*2) with a
well-characterized mutant isoform of Zfp423 lacking the
SMAD-binding domain47 (SBD, hereafter Zfp423DSBD) and
assessed their tumorigenicity in vivo. Contrary to the major
antigliomagenic effect observed with the overexpression of the
full-length protein, overexpression of mutant Zfp423 did not affect
the tumorigenicity of AstroEGFR*2 astrocytes (Fig. 7b), validating
the model in which the SMAD-dependent differentiating function
of Zfp423 is critical for its antigliomagenic properties.
Discussion
HGG constitute an unmet challenge in oncology. Beyond the
obvious difﬁculty linked to the anatomical site and the
remarkable invasiveness of these tumours, two key problems
have hampered progress so far: (i) the marked heterogeneity of
these tumours, which implies the development of several
subgroup-targeted approaches, and (ii) the virtual inaccessibility
of early-stage lesions, with the attending inability to trace tumour
history and deﬁne the critical gene circuits that drive initial
establishment of the tumour. Notably, although many mouse
models have proven invaluable in dissecting central aspects of this
human disease, the experimental features of most of them
precluded a thorough characterization of disease dynamics. This
applies especially to the chromatin level of regulation, despite its
emergence as a fundamental domain of perturbation that is
raising major therapeutic hopes. Indeed, although cancer-speciﬁc
chromatin maps, including for PRC2-dependent H3K27 tri-
methylation, are rapidly accumulating for both human and
murine tumours, they most often describe endpoints of disease
progression and are seldom related to transcriptional output in
terms of mechanistically tested and functionally validated circuits.
Here we advance signiﬁcantly our understanding of PRC2
contribution to gliomagenesis with an unbiased characterization
of the PRC2-dependent circuits. Speciﬁcally, we combined the
informative power of a mouse model featuring homogeneous cell
populations of differential tumorigenic potential with a
computational pipeline for the systematic integration of RNAseq
and ChIPseq proﬁles with discovery tools for TF motif
enrichment. This yielded two key insights. First, it enabled us
to functionally partition the effect of PRC2 silencing, by showing
that two critical developmental domains, one centred on the
morphogenetic cues that enable migration and the other centred
on dedifferentiation, were under direct PRC2 control. Impor-
tantly, both have been linked to core features of HGG, such as the
marked propensity for invasiveness and the aberrant re-expres-
sion of elements of the pluripotency network33. Second, it led to
the identiﬁcation of a single TF, Zfp423, that was also under direct
PRC2 control and accounted for a signiﬁcant portion of the
transcriptional dysregulation that underlies the transition from
tumorigenic astrocytes to GPCs. Importantly, we found that
Zfp423 downregulation correlated with a worse prognosis, both in
two independent mouse models and in two very large cohorts of
human patients. The human homologue of Zfp423, ZNF423, had
been previously identiﬁed as a positive prognostic factor for
neuroblastoma44; hence, our results now extend the functional
relevance of this gene to a wholly different class of tumours.
The modular architecture of Zfp423 and ZNF423, whose
Kru¨ppel-like C2H2 zinc ﬁnger clusters mediate interaction with
distinct transcriptional partners62, allowed us to mechanistically
deﬁne the requirement of the BMP signalling axis for the anti-
gliomagenic activity of Zfp423, as only the full-length protein but
not its SMAD mutant form was able to prolong survival. This
ﬁnding is particularly interesting in light of our results
demonstrating PRC2-silencing of Bmp4 in our primary tumour
samples and of previous data on the aberrant recruitment of
PRC2 to the BMPR1B receptor gene28, pointing to a synergic
impact of Polycomb both on core members of the BMP signalling
pathway and on one of their critical downstream effectors.
Finally, our ﬁndings also uncovered a signiﬁcant degree of
heterogeneity within Ink4/Arf / ; EGFR* gliomagenesis,
which we harnessed at the molecular level to deﬁne the
mechanisms and context speciﬁcity of Zfp423 antigliomagenic
activity. As to the former, we found that Ink4/Arf / ; EGFR*
tumorigenic astrocytes, despite their overall similarity, display
transcriptional speciﬁcities that are differentially retained in the
gliomas they originate, suggesting that they represent differen-
tially primed entry points of tumorigenesis. Consistently, this
heterogeneity is carried through the primary gliomas, which
encompass a relatively wide range of high-grade histopathological
subtypes and also recapitulate, to different extents and for
different parts, the signatures used to classify human HGG.
This transcriptomic dissection of glioma heterogeneity was
functionally validated with the observation that Zfp423 exerts the
strongest antigliomagenic activity only in the context of the least
tumour-primed astrocytes, in which it antagonizes, in an
exquisitely SMAD signalling-dependent manner, a very
signiﬁcant portion of the gliomagenic programme that includes
Sox2, a well-established glioma oncogene, and several other
differentiation-promoting factors that are speciﬁcally down-
regulated in gliomas. However, the context speciﬁcity displayed
in this experimental model did not prevent the deﬁnition of a
general prognostic impact for ZNF423 downregulation, which
was conﬁrmed in two large independent human cohorts. The
context effect of Zfp423 is consistent with accumulating evidence
on the extreme heterogeneity that characterizes gliomas, with a
growing number of TFs being shown to play critical roles but in
highly selected cases, as in the instance of the six TFs that
underlie transcriptomic changes uniquely in the mesenchymal
subtype HGG26 or, even more strikingly, the FGFR-TACC
oncogenic fusion that was identiﬁed in three patients from a
large cohort of HGG patients64. Indeed, especially in light of the
signiﬁcant challenge posed by this remarkable heterogeneity, we
believe that our approach of identifying candidate master
regulators, along with their relevant networks, by comparing
initiating cells with their corresponding tumours further advances
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10753 ARTICLE
NATURE COMMUNICATIONS | 7:10753 | DOI: 10.1038/ncomms10753 | www.nature.com/naturecommunications 11
the functional reclassiﬁcation of gliomas on the basis of
physiopathologically meaningful TF-centred pathways.
Methods
Human cells. Human GBM cell lines were obtained from Rossella Galli’s lab
(San Raffaele Scientiﬁc Institute, Milan, Italy) and were grown as described in ref. 65.
Human astrocytes were obtained from ScienCell Research Laboratories (1810).
Murine cell culture and manipulation. Primary astrocytes, GPCs and NPs were
derived and cultured as described previously66,67,43 (see also Supplementary
Methods). For the astrocyte cultures, we made use of a classic protocol ﬁrst
descbribed in 1980. Five- to 7-day-old pups were killed, each brain was removed
from the head and transferred into a cell culture dish containing sterile Dulbecco’s
PBS (Lonza). Cerebral cortices were isolated from the rest of the brain and placed
into a 1.5-ml tube containing 0.5ml of astrocyte culture medium (15% North
American fetal bovine serum (FBS) (Gibco), 2mM glutamine, (Lonza), 0.6%
glucose (Sigma), 100Uml 1 potassium penicillinþ 100Uml 1 streptomycin
sulfate (Lonza) in basal medium Eagle’s (Gibco)). They were mechanically
dissociated with scissors and through pipetting; the dissociated tissue was plated
into a T-25 ﬂask and incubated in a humidiﬁed incubator at 37 C with 5% CO2.
Medium was changed 3 days after plating and every other day thereafter until day 9
of culture. Cells were passaged every 4–5 days starting from day 10 of culture at a
1:2 or 1:3 ratio. The cells were rinsed with Dulbecco’s PBS and detached in trypsin–
versene 1:10 (Sigma and Lonza, respectively); after detachment, the dissociation
into single cells was achieved through pipetting. Trypsin was inactivated by adding
FBS (Gibco, 1 volume per volume of trypsin) and cells were collected by
centrifugation at 280 g for 5min. The cell pellet was resuspended in fresh astrocyte
medium and cells were plated in 6-well plates. EGFR*- or ZFP423/ZFP423dSBD-
expressing retroviral particles were generated using the retrovirus producer cell line
Phoenix-Eco. Established astrocyte cultures (after passage 2) were infected using
the viral supernatant ﬁltered through a 0.45-mm ﬁlter. Astrocytes were trypsinized
as described before; 5 105 cells were resuspended in 3ml of viral supernatant
supplemented with 8 mgml 1 Polybrene (Sigma) and plated in a well of a 6-well
plate. The supernatant was removed and replaced with fresh supernatant at each
new collection. Astrocytes were kept in culture for less than ten passages before
being used for in-vivo experiments and next generation sequencing proﬁling.
GPC cultures were obtained and maintained as described in Pollard et al.67.
Mice injected with tumorigenic astrocytes were killed at the onset of neurological
symptoms. The tumour mass was dissected from the brain and a small piece was
put in a 1.5-ml tube containing 0.5ml of Accutase (Sigma). The tissue was
mechanically dissociated with scissors and through pipetting, passed through a
70-mm cell strainer and single cell suspension was collected in a 50-ml tube. After
centrifugation (300 g for 5min), cells were resuspended in glioma-initiating cell
medium (1 B27, 1 N2 (Gibco), 20 ngml 1 of both EGF and murine ﬁbroblast
growth factor-2, 100Uml 1 potassium penicillinþ 100 mgml 1 streptomycin
sulfate in neurobasal medium (Gibco)) and plated in one or two wells of a six-well
plate, coated with laminin (Roche). Plates were kept in a humidiﬁed incubator
37 C with 5% CO2; medium was changed 2 days after plating and every other day
thereafter. Cells were passaged at 80–90% conﬂuency at a ratio ranging from 1:3 to
1:6. They were detached with Accutase and dispersed into single cells by gentle
pipetting; after centrifugation at 300 g for 5min, cells were resuspended in glioma-
initiating cell medium and plated as described above. GPCs were kept in culture for
less than ten passages before being used for in-vivo experiments and next
generation sequencing proﬁling. Differentiation was performed according to the
protocol published in the same paper. In particular, astrocytic differentiation was
performed by adding FBS or BMP4 to the culturing medium, whereas neuronal
differentiation was achieved through growth factor withdrawal. The same protocol
was used for the differentiation of embryonic neural precursors.
EGFR*, Pdgf-b, Zfp423 or Zfp423DSBD retroviral particles were generated
using the retrovirus producer cell line Phoenix-Eco. Supernatant was collected and
used directly or after ultracentrifugation. Differentiation of NP was performed as
described in ref. 67.
In vivo experiments. Experiments involving animals were carried out in accor-
dance with the Italian Laws (D.lgs. 26/2014), which enforces Dir. 2010/63/EU
(Directive 2010/63/EU of the European Parliament and of the Council of 22
September 2010, on the protection of animals used for scientiﬁc purposes).
Speciﬁcally, the project was notiﬁed to the Ministry of Health before the
implementation of the current legislation. As the new legislation does not apply to
projects approved before its enactment, for such projects only a notiﬁcation of the
experiments to the Ministry of Health was required (in accordance with the D.L.vo
116/92 (and following additions), which enforced EU 86/609 Directive), and this
requirement was dutifully fulﬁlled.
Tumour formation was induced by stereotaxical injection of 5 105
AstroEGFR* or GPCs into the caudate of Cd1-Nude HO, 5-week-old female mice
(coordinates: 0.7mm back, 3mm left and 3.5mm deep from the bregma). Brains
were isolated at the onset of disease symptoms and ﬁxed in 4% buffered formalin.
Samples were parafﬁn embedded, sectioned, stained for haematoxylin and eosin,
and histopathologically classiﬁed by pathologists.
RNA and protein extraction. RNA was extracted from all the lines using the
RNeasy Mini Plus Kit (Qiagen) according to the manufacturer’s speciﬁcations.
Quality and concentration of RNA was assessed using a NanoDropSpec-
trophotometer (NanoDrop Technologies).
Proteins were extracted as follows: cells were harvested from the plate and
centrifuged at 300 g for 5min, then washed in PBS and lysed in RIPA buffer plus
protease inhibitors cocktail (Sigma). Lysates were sonicated using the Bioruptor
Sonication System (UCD200) for three cycles of 30 s with 60 s pause at high power.
Lysates were centrifuged at 13,000 g for 15min and supernatants were transferred
to a new tube. Protein quantiﬁcation was performed using the Bradford protein
assay (BioRad) following the manufacturer’s instructions.
Complementary DNA preparation and qPCR. Retrotranscribed cDNAs have
been obtained from 1 mg of total DNA-depleted RNA using the superscript VILO
retrotranscription kit from Life Technologies according to the manufacturer’s
instructions.
For quantitative reverse transcriptase–PCR (qRT–PCR) analysis, a total amount
of cDNA corresponding to 5 ng of starting RNA has been used for each reaction.
FAST SYBR green master mix from Life Technologies and 10 mM primer pairs have
been used. The qPCR reactions have been performed on an Applied Biosystems
7500 Real-Time PCR machine following the standard ampliﬁcation protocol
(primer list and Taqman Assays ID provided in Supplementary Tables 1 and 2).
RNAseq and ChIPseq. Library preparation for RNA sequencing was performed
using RiboZero and Single Stranded kits (Illumina) according to the manu-
facturer’s instructions. Validation of RNAseq results has been performed through
qRT–PCR analysis.
For ChIPseq, cells were harvested and resuspended in PBS containing 1%
formaldehyde for ﬁxation and quenched with 125mM glycine. Cells were lysed and
sonicated using the Covaris Sonicator, to generate 250 bp DNA fragments.
Chromatin was incubated overnight at 4 C with the antibodies (H3K27me3 (Cell
Signalling) and H3 total (Abcam)) and recovered the day after using Dynabeads
Protein G (Life Technologies). Immunocomplexes were eluted, de-cross-linked and
puriﬁed using Qiaquick PCR Columns (Qiagen) according to the manufacturer’s
instructions. DNA libraries were prepared according to ChIPseq Sample
Preparation Guide (Illumina) and sequenced on an Illumina GA-II or HiSeq 2000
platform. Validation of ChIPseq results has been performed through qPCR
analysis: 5 ng DNA have been used for each reaction. FAST SYBR green master mix
from Life Technologies and 10 mM primer pairs have been used. The qPCR
reactions have been performed on an Applied Biosystems 7500 Real-Time PCR
machine following the standard ampliﬁcation protocol. Primer lists for qRT–PCR
and ChIP–qPCR are provided in Supplementary Tables 1 and 3. A detailed
description of computational analysis is available as Supplementary Methods. Gene
lists from ChIPseq and RNAseq analysis are available as Supplementary Data 1.
IPA analyses are available as Supplementary Data 2. ChIPseq and RNAseq data
have been deposited in the GEO database (GSE76292).
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